Market Intelligence
MCED Watch
Multi-cancer early detection has generated one of the largest population-scale clinical investments in oncology history — across three competing technologies, two parallel markets, and a 2026 verdict window. Zero routine reimbursements.
Curated milestone-trial data through June 2026; pipeline status counts refresh daily from ClinicalTrials.gov.
Approximately 402k planned participants span the major MCED trials tracked here (a mix of target and actual enrollment). The NHS alone randomized 142,000. GRAIL has run three population-scale studies. Chinese companies are running a parallel evidence campaign with 40,000+ patients across multi-omics platforms. Elypta is testing a completely different biology — glycan biomarkers in urine.
And yet not one health system in the world has approved routine reimbursement for a multi-cancer early detection test. The gap between clinical investment and commercial reality is the defining tension of this market — and 2026 is when the first major answers arrive.
~402k
Planned participants, major MCED trials
36
Completed
Data in hand
16
Active
Enrolled, following up
35
Recruiting
Actively enrolling
Where is the evidence being built?
By planned participants across major trials
Three technology bets
Competing approaches to detecting cancer signals in blood
GRAIL approach — cancer-specific DNA methylation patterns in blood
NHS Galleri Trial · PATHFINDER 2 · REACH Study · SUMMIT Study · STRIVE Study · INFORM Study
DNA + protein + metabolite signals combined — dominant Chinese approach
MERCURY Study · PROFOUND Study · PREVENT Study · Adela Multi-Cancer Study
GAGomes — glycosaminoglycan patterns in urine, no blood draw required
LEVANTIS (GAGomes)
The verdict calendar
When key trials complete
2025
UK validation alongside CT lung screening
GAGomes urine-based MCED — alternative tech verdict
2026 ← verdict year
The readout that anchors the NHS adoption decision
US FDA review package for Galleri
Chinese multi-omics MCED — parallel market verdict
2027
China multi-omics in average-risk population
2030
CMS Medicare coverage determination study
The 2026 verdict window
NHS Galleri Trial and PATHFINDER 2 both complete in 2026 — combined 178k planned participants. If both read positive and generate coverage recommendations, MCED could move toward reimbursed screening in two of the world’s largest healthcare markets. If they don’t, the sector faces a reset: GRAIL’s valuation, the Chinese pipeline, and the entire screening reimbursement strategy all come into question.
What this tells us
China is running a parallel MCED market — and isn’t waiting.
MERCURY, PROFOUND, and PREVENT together enroll over 40,000 patients in Chinese multi-omics MCED studies. The technology is different from GRAIL (protein + DNA + metabolite rather than methylation alone), the companies are different, and the regulatory pathway is different. China does not need FDA or NHS approval to build a commercial MCED market. If these studies generate compelling performance data, Chinese MCED will reach scale well before Western reimbursement decisions are made.
The methylation bet is enormous — and concentrated in one company.
GRAIL has staked the largest single-company clinical investment in MCED history on methylation-based detection. NHS Galleri (142k), PATHFINDER 2 (36k), and REACH (50k) are all GRAIL or GRAIL-adjacent. If methylation-based cfDNA is the right approach, GRAIL has a near-unassailable head start. If a different biology turns out to be superior — multi-omics, GAGomes, WGS — the entire evidence base has to be rebuilt.
The pharma gap is the most telling absence.
Every other diagnostic category in this signal — ctDNA, MRD, CGP — has pharmaceutical companies embedding assays in drug trials. MCED has none. No pharma company has a treatment that is paired with an MCED test. This means MCED has no CDx pathway, no drug-diagnostic co-development, and no pharma commercial backing. Its entire commercial path runs through screening reimbursement — the hardest regulatory journey in medicine, with the longest timelines and the highest clinical evidence bar.
High-risk populations are the defensible first step.
INFORM (Dana-Farber, high-risk hereditary patients) and Sentinel (military population) test Galleri in populations where early detection has a clearer cost-benefit argument. Average-risk population screening requires enormous evidence for cost-effectiveness. High-risk populations have higher pre-test probability, more compelling economics, and a more straightforward regulatory argument. Expect initial coverage decisions — if any come — to start here.
Key trials
11 trials spanning three technologies and four geographies — the milestone MCED validation studies.
NHS Galleri Trial
GRAIL / NHS EnglandLargest MCED trial ever run. 142,000 NHS patients randomized to Galleri vs. standard screening. A positive readout could support regulatory review, coverage discussions, and broader NHS adoption — the global proof point the field is waiting on.
STRIVE Study
GRAILGRAIL's foundational biobank study — 99,000 women enrolled at mammography screening. Generated the methylation data underpinning Galleri's detection algorithm. The largest completed MCED study.
REACH Study
GRAILMedicare-population study at 61 sites. Specifically designed to generate the real-world evidence CMS needs for coverage determination.
PATHFINDER 2
GRAILGRAIL's US screening pivotal study — the confirmatory data package supporting FDA review and potential US adoption of Galleri, which is already under FDA premarket review.
PROFOUND Study
Shanghai Weihe Medical LaboratoryChinese multi-omics MCED model development and validation. Peripheral blood multi-omics with machine learning. Building a parallel evidence base independent of GRAIL.
MERCURY Study
Nanjing Shihejiyin TechnologyChina's flagship MCED study — multi-omics liquid biopsy in an average-risk population. Signals that the MCED race is global, not just US/UK.
SUMMIT Study
University College LondonUK academic validation alongside low-dose CT lung screening. Tests whether liquid biopsy adds value on top of existing screening infrastructure.
PREVENT Study
Guangzhou Burning Rock DxBurning Rock Dx — China's leading ctDNA company — running its own MCED validation study. 12,500 asymptomatic individuals with OverC multi-cancer blood test.
LEVANTIS (GAGomes)
ElyptaTests GAGomes — glycosaminoglycan biomarkers from urine — rather than blood DNA. A completely different biological approach to MCED. If it works, it diversifies the technology bet beyond cfDNA.
Adela Multi-Cancer Study
Adela, Inc.US cfDNA platform validation across 20 cancer types, 17 sites. Adela is building a competing US MCED assay — this study is their performance validation dataset.
INFORM Study
Dana-Farber Cancer InstituteHigh-risk hereditary cancer population. Tests Galleri in patients with genetic predisposition. Smaller but strategically important — high-risk populations are the most defensible first reimbursement target.
Methodology: Status counts from ClinicalTrials.gov, condition “multi-cancer early detection.” Note: the raw count includes tangentially related studies (screening behavior interventions, single-cancer studies); the 11 milestone trials are curated for relevance. Enrollment figures from registry entries. Geography and technology classifications are editorial. Data refreshes daily. Last updated: June 17, 2026.